Pan-Cancer Liquid Biopsy Sensitivity Breaks 90%
Grail's upgraded Galleri liquid biopsy achieves 91.3% sensitivity across 14 cancer types, up 12 percentage points from the previous version, with false positive rate below 0.5%.
Liquid biopsy company Grail released updated data on January 6 for its Galleri multi-cancer early detection test. The upgraded Galleri can simultaneously detect 14 cancer types with a combined sensitivity of 91.3%, a 12-percentage-point improvement over the 2027 version.
The most significant breakthrough is in early cancer detection capability. For stage I cancers (earliest stage), the upgraded Galleri's sensitivity increased from 43% to 72%. Among all 14 cancer types, pancreatic cancer showed the most dramatic improvement, jumping from 38% to 67%.
Grail's Chief Science Officer attributed the sensitivity gains to two factors: expansion of detection biomarkers from cfDNA methylation to combined analysis of cfDNA fragmentomics and protein markers, and upgrades to the AI classification algorithm with 3x more training data.
The upgraded Galleri maintains a false positive rate below 0.5%, meaning only 1 in 200 healthy individuals would receive a false positive result. Grail plans to bring the upgraded test to market in Q2 2028 at approximately $1,200.
The US Preventive Services Task Force (USPSTF) is evaluating whether to include multi-cancer liquid biopsy in routine screening recommendations.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.